Gastric tumor
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: (1) Diagnosed gastric cancer as clinical T1a or gastric adenoma (2) Only one lesion will be performed by ESD. (3) Patients are accepted to enrollment and registration for this study. (4) Patients can be follow up for 56 days after ESD.
Exclusion criteria
Exclusion criteria: (1) Patients with active peptic ulcer (2) Patients with the history of gastrectomy (3) The lesion which are recurrence of endoscopic resection before (4) Patients with intake of mucosal protective agent or antacid (5) Patients with severe anemia (6) Patients with severe liver dysfunction (7) Patients with severe renal dysfunction (8) Patients with allergy for Vonoprazan (9) Patients without written informed consent (10) Patients with the possibility of the pregnancy or the pregnancy and lactating (11) Ineligible patients certified by doctors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the rate of delayed bleeding after ESD by Vonoprazan at 6 weeks, compared with proton pomp inhibitor at 8 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess the rate of ulcer healing after ESD by Vonoprazan at 6 weeks, compared with proton pomp inhibitor at 8 weeks. | — |
Countries
Japan
Contacts
Kyoto Prefectural University of Medicine Department of Gastroenterology and Hepatology